A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Etonogestrel (Primary) ; Efavirenz; Nevirapine
- Indications Pregnancy
- Focus Pharmacokinetics
- 07 Mar 2018 Results (n=39) assessing the potential associations between single nucleotide polymorphisms involved in efavirenz and etonogestrel metabolism with the observed alteration in etonogestrel pharmacokinetics in women from this study, presented at the 25th Conference on Retroviruses and Opportunistic Infections.
- 31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.